fda bpc-157 status february 2026 Peptides in the Limelight: US May Ease Restrictions on Several Peptides Updated 2026 FDA Category 2
Description
This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available
Aaron Mangold, MD, is a board-certified dermatologist and an assistant professor of dermatology at the Mayo Clinic in Arizona.
World J Gastroenterol 2017 (in press)
Safety notes: Ashwagandha can cause digestive upset or drowsiness
Category lists, enforcement discretion, and the gray zone people keep misreading If youve been tracking peptide news, youve likely seen a recurring claim: FDA removed peptides from Category 2, so theyre allowed again. Thats not how the legal mechanics work
